Prof. Huntington is the head of the Cancer Immunotherapy Laboratory at the Biomedicine Discovery Institute at Monash University, Australia. He is an international leader on natural killer (NK) cell biology with notable contributions to: regulatory mechanisms of IL-15 signalling in NK cells, identification of human and murine NK cell differentiation pathways, novel xenograft models to study human haematopoiesis and identification of multiple checkpoint in NK cell activation and tumour immunity. Prof. Huntington leads a research program aimed at deciphering the regulatory networks that control NK cell immunity and a drug discovery program using cutting-edge in vivo screens for novel checkpoints in NK cell activation for targeting in cancer immunotherapy. Prof. Huntington is President of MIN (Melbourne Immunotherapy Network), serves as project director for several pharmaceutical collaborative research programs at The Walter and Eliza Hall Institute and is a co-founder and chief scientific officer of oNKo-Innate Pty Ltd